Document is current
Any future updates will be listed below
-
Authors
de Carvalho, Andressa Alves https://orcid.org/0000-0003-2828-479X
de Carvalho, Wanessa Alves https://orcid.org/0000-0002-4507-8149
Donato, Glaudir https://orcid.org/0000-0001-8081-9734
de Lira Sobral, Rafael Freire https://orcid.org/0009-0006-5732-9968
Mariz, Pedro Fernandes https://orcid.org/0000-0002-8854-3397
Macedo, Ariane Vieira Scarlatelli https://orcid.org/0000-0002-3453-8488
Melo, Marcelo https://orcid.org/0000-0001-8809-8783
Lopes, Renato D. https://orcid.org/0000-0003-2999-4961
- License Information
-
More Information
Article History
Received: 23 June 2025
Accepted: 29 October 2025
First Online: 13 November 2025
Declarations
:
: RDL reports research grants or contracts from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi-Aventis; funding for educational activities or lectures from Pfizer, Daiichi Sankyo, and Novo Nordisk; and funding for consulting from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, and Novo Nordisk. The other authors declare no conflict of interest.
